HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4-9 analogue ORG 2766 in IDDM patients with neuropathy.

Abstract
In this study we report a randomized double-blind, placebo-controlled trial to evaluate the effect of ORG 2766 in IDDM patients with peripheral neuropathy. Sixty-two patients were selected based on the following criteria: abnormal vibration perception threshold above the 95th-percentile adjusted for age and/or abnormal warm temperature threshold, both measured in the right hand. The patients were randomized into two treatment groups after baseline studies: Group 1 was treated with placebo and Group 2 was treated with 3 mg of the ACTH4-9 analogue ORG 2766 every 24 h. The total study period was 1 year. After 1 year of treatment there was a significant improvement in vibration threshold in Group 1 compared to Group 2. No other parameters improved in the study period. The number of patients selected may have been too small to detect a more important treatment effect. We conclude from this study that ORG 2766 can improve vibration threshold, indicating large myelinated fibre function, but does not affect any of the other neurophysiological function tests.
AuthorsB Bravenboer, P H Hendrikse, P L Oey, A C van Huffelen, C Groenhout, W H Gispen, D W Erkelens
JournalDiabetologia (Diabetologia) Vol. 37 Issue 4 Pg. 408-13 (Apr 1994) ISSN: 0012-186X [Print] Germany
PMID8063043 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anticonvulsants
  • Peptide Fragments
  • Org 2766
  • Adrenocorticotropic Hormone
Topics
  • Adrenocorticotropic Hormone (analogs & derivatives, therapeutic use)
  • Adult
  • Anticonvulsants (therapeutic use)
  • Diabetes Mellitus, Type 1 (complications, drug therapy)
  • Diabetic Neuropathies (drug therapy, etiology)
  • Double-Blind Method
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Peptide Fragments (therapeutic use)
  • Perceptual Disorders (drug therapy)
  • Psychomotor Performance
  • Sensory Thresholds

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: